Abstract
Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Volume: 10 Issue: 2
Author(s): Charles J. Malemud
Affiliation:
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Abstract: Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Export Options
About this article
Cite this article as:
J. Malemud Charles, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (2) . https://dx.doi.org/10.2174/1871523011107020073
DOI https://dx.doi.org/10.2174/1871523011107020073 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Glycolipid Ligands for Natural Killer (NK) T Cells in the Suppression of Autoimmune Diseases
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Methotrexate Hepatotoxicity in Rheumatoid Arthritis: An Analysis of the Physicians’ Policy
Current Rheumatology Reviews Constrained Analogs of Osteogenic Peptides
Current Medicinal Chemistry Affinity-Based Methods in Drug-Target Discovery
Current Drug Targets Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Actions of Adjunctive Nutritional Antioxidants in Periodontitis and Prevalent Systemic Inflammatory Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Therapeutic Proteins in Tumors and Targeted Therapeutic Agents for Cancer Patients
Protein & Peptide Letters Pharmacogenomics and Sepsis-Induced Renal Failure: Effects of β 2-Adrenoceptor Function on the Course of Sepsis
Current Pharmacogenomics and Personalized Medicine Anti-Inflammatory Effects of Novel Standardized Platelet Rich Plasma Releasates on Knee Osteoarthritic Chondrocytes and Cartilage in vitro
Current Pharmaceutical Biotechnology Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science T-Cell Zeta Chain Expression, Phosphorylation and Degradation and their Role in T-Cell Signal Transduction and Immune Response Regulation in Health And Disease
Current Signal Transduction Therapy Nitrogen, Oxygen or Sulfur Containing Heterocyclic Compounds as Analgesic Drugs Used as Modulators of the Nitroxidative Stress
Mini-Reviews in Medicinal Chemistry Preface
Current Pharmaceutical Design Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Immune Disturbances in Chronic Pain: Cause, Consequence or Both?
Current Immunology Reviews (Discontinued) Therapeutic Targets in Inflammatory Disease
Current Medicinal Chemistry Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Potential Effect of Anti-Inflammatory Treatment on Reducing the Cardiovascular Risk in Rheumatoid Arthritis
Current Vascular Pharmacology